Core B: Clinical Core

核心 B：临床核心

• 批准号: 8849139
• 负责人: JAMES J LAH
• 金额: $ 37.43万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8849139
• 关键词: Address; Affect; African; African American; Alzheimer disease prevention; Alzheimer' s Disease; Amyloid beta-Protein; Area; Autopsy; Basic Science; Biological; Biological Markers; Blood; Blood specimen; Brain; Cerebrospinal Fluid; Clinical; Clinical Data; Clinical Pathology; Clinical Research; Clinical Trials; Cognition; Cognitive aging; Collection; Communities; Cross-Sectional Studies; Data; Data Quality; Dementia; Diagnosis; Disease; Education; Elderly; Elements; Enrollment; Evolution; Failure; Funding; Genetic; Genotype; Goals; Hispanics; Impaired cognition; Individual; International; Magnetic Resonance Imaging; Memory Loss; Multicenter Studies; Nerve Degeneration; Neurodegenerative Disorders; Onset of illness; Participant; Pathological Staging; Patients; Pharmaceutical Preparations; Play; Population; Positioning Attribute; Process; Production; Public Health; Recruitment Activity; Research; Research Personnel; Research Support; Resources; Risk; Role; Sampling; Specimen; Staging; Symptoms; Therapeutic; United States National Institutes of Health; Work; abstracting; base; cohort; combat; data management; drug testing; effective therapy; enhancing factor; improved; innovation; mild cognitive impairment; neuroimaging; neuropathology; outreach; peptide A; pre-clinical; success; volunteer

SUMMARY/ABSTRACT: CLINICAL CORE (CORE B) The primary goals of the Emory ADRC Clinical Core are to support and enhance research efforts to understand the causes of Alzheimer's disease and related neurodegenerative disorders in order to develop effective treatments. To accomplish these goals, the Clinical Core maintains a cohort of volunteers who allow investigators to examine the process of normal and pathological cognitive aging, provide essential biological specimens and neuroimaging data, and serve as participants in promising clinical trials. The Clinical Core contributes to local, national, and international studies and reflects NIA-defined network-wide priorities. In the current funding period, the Core has provided top-quality clinical data and biological samples to national coordinating centers, and has maximized community engagement and participation of African-American older adults in ADRC-sponsored research and related projects. Specific Aims for this renewal are to 1) continue to maintain a cohort of well-characterized participants to support efforts to understand normal cognitive aging and decline due to AD and related disorders; 2) develop innovative approaches to increase the participation of African Americans in AD research; and 3) establish a Longitudinal Biomarker Collection to support research and improve understanding of the early stages of pathological cognitive aging. We will focus our efforts on preclinical disease and mild cognitive impairment since treatments are more likely to be successful if implemented at an early stage. We also plan to double the current cohort to include 50% African Americans to address stark racial imbalances in understanding clinical, pathological, and genetic features of AD and to make data available for multicenter studies. As part of this effort, we will collect data to define elements that improve success in recruiting and engaging African-American research volunteers. Longitudinal biomarker sampling of blood, CSF, and neuroimaging will provide a powerful resource since cross-sectional studies limit our ability to identify predictors of AD onset and progression. The themes and goals that are proposed for the Clinical Core are consistent with the overall focus of the Emory ADRC, and it will serve as a powerful proponent for basic and clinical research efforts to advance our abilities to diagnose and treat patients suffering from AD and other neurodegenerative dementing diseases.

摘要/摘要：临床核心(核心B) 埃默里ADRC临床核心的主要目标是支持和加强研究工作 了解阿尔茨海默病和相关神经退行性疾病的病因，以便发展 有效的治疗方法。为了实现这些目标，临床核心维护着一群志愿者，他们允许 研究人员对正常和病理性认知老化的过程进行研究，提供必要的生物学依据 样本和神经成像数据，并作为有希望的临床试验的参与者。临床核心 为地方、国家和国际研究做出贡献，并反映NIA定义的网络范围内的优先事项。在 在目前的资助期内，核心为国家提供了高质量的临床数据和生物样本 协调中心，并最大限度地提高了社区的参与度和非裔美国老年人的参与 成人参与ADRC赞助的研究和相关项目。 此次更新的具体目标是：1)继续保持一批具有良好特点的参与者，以 支持了解阿尔茨海默病及相关障碍引起的正常认知老化和衰退的努力；2)发展 创新办法，增加非洲裔美国人参与AD研究；和3)建立 纵向生物标记物收集，以支持研究和提高对早期阶段的了解 病理性认知老化。我们将重点关注临床前疾病和轻度认知障碍。 因为如果在早期阶段实施，治疗更有可能成功。我们还计划将 目前的队列包括50%的非裔美国人，以解决在理解临床、 阿尔茨海默病的病理学和遗传学特征，并为多中心研究提供数据。作为这项工作的一部分 通过努力，我们将收集数据，以确定在招聘和吸引非裔美国人方面取得成功的因素 研究志愿者。血液、脑脊液和神经成像的纵向生物标记物采样将提供强大的 资源，因为横断面研究限制了我们识别AD发病和进展的预测因素的能力。这个 为临床核心提出的主题和目标与埃默里学院的总体重点一致 ADRC，它将成为基础和临床研究努力的有力支持者，以提高我们的能力 诊断和治疗阿尔茨海默病和其他神经退行性痴呆患者。